soluble guanylate cyclase

MGV354 is a soluble activator of guanylate cyclase(sGC) with EC 50 s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively [1] [2].

LY83583 is a soluble guanylate cyclase competitive inhibitor with IC50 of 2 µM.

Nelociguat (BAY60-4552)(BAY60-4552) is a soluble guanylate cyclase stimulator (sGC stimulator). Soluble guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO) signalling pathway.

BI 703704, a soluble guanylate cyclase (sGC) activator, inhibits the progression of diabetic nephropathy in the ZSF1 rat [1].

(Rac)-MGV354 (MGV354) is the racemate of MGV354. MGV354 is a soluble activator of guanylate cyclase (sGC)(EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively).

NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor (IC50: 30 nM and 200 nM for basal and NO-stimulated enzyme activity) commonly used in nitric oxide signaling pathway research. It inhibits sGC activity in mouse cerebellum homogenates and neuronal NO synthase (IC50: 17 nM and 20 nM), inhibits 3-morpholino-sydnonimine (SIN-1)-elicited cyclic GMP formation in human cultured umbilical vein endothelial cells (IC50: 30 nM), and completely inhibits NO-dependent relaxant responses in non-vascular smooth muscle (1 μM). NS-2028 also decreases vascular endothelial growth factor-induced angiogenesis and permeability.

Praliciguat (IW-1973) stimulates sGC in HEK-293 cells (EC50: 197 nM). Praliciguat is an effective and orally active soluble guanylate cyclase stimulator. It also enhances NO signaling and acts as a vasodilator.

Runcaciguat is a soluble guanylate cyclase stimulator. Runcaciguat combines with selective partial adenosine A1 receptor agonists and can be used in studies about cardiovascular and renal diseases.

Cinaciguat (BAY 58-2667) (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in Clinicalal development for acute decompensated heart failure.

sGC activator 2 (Compound 16a) acts as an activator of soluble guanylate cyclase (sGC), enhancing the production of cGMP and exhibiting vasoprotective and anti-inflammatory properties.

KMUP-1 is a xanthine derivative known for its vasodilatory properties. It functions as a phosphodiesterase (PDE) inhibitor and an activator of soluble guanylate cyclase (sGC), engaging the NO/sGC/cyclic guanosine monophosphate pathway. Additionally, KMUP-1 can open K+ channels and has the potential to alleviate ischemia-induced cardiac myocyte apoptosis (apoptosis). This compound is useful in cardiovascular and anti-inflammatory research.

Vericiguatimpurity-3 is an impurity of Vericiguat. Vericiguat (BAY1021189) is a potent, orally active stimulator of soluble guanylate cyclase (sGC).

sGC stimulator 1 is a carbonyl sulfide (COS)/H2S donor hybrid soluble guanylate cyclase (sGC) stimulator with an EC50 of 496 nM. It demonstrates significant H2S release properties and reduces fibrosis in cardiac fibroblasts treated with TGF-β1 by increasing H2S levels. sGC stimulator 1 exerts antifibrotic effects by activating sGC and elevating H2S concentrations. This compound is applicable for heart failure (HF) research[1].

(R)-BAY-747 ((R)-BAY 1165747) is the (R)-enantiomer of BAY-747. BAY-747 is an orally active, blood-brain barrier penetrating stimulator of soluble guanylate cyclase (sGC).

LOXL2/sGC modulator-2 (Compound 9k) is a selective, orally active dual-target modulator of lysyl oxidase-like protein 2 (LOXL2) and soluble guanylate cyclase (sGC). It inhibits LOXL2 with an IC50 of 0.1 μM and acts as an sGC activator. This compound can improve vascular remodeling and reduce pulmonary arterial pressure while downregulating PKG1, PCNA, α-SMA, collagen I, and fibronectin levels. LOXL2/sGC modulator-2 is useful for studying pulmonary arterial hypertension.

S-3448 is a derivative of Ataciguat and functions as an activator of soluble guanylate cyclase (sGC). It can activate both heme-containing and heme-deficient sGC independent of NO and heme. S-3448 is utilized in research related to cardiovascular diseases such as arterial hypertension and pulmonary arterial hypertension.

Ataciguat (HMR-1766) (HMR-1766) is a potent and specific soluble guanylate cyclase (sGC) activator.

BAY 41-8543 is a nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC).

Phenylaminojuglone AJ-2 is a nitric oxide synthase inhibitor that can interact with soluble guanylate cyclase, β-adrenergic receptors, CaV1.2 calcium channels, KV channels, and KCa channels. It blocks extracellular Ca2+ influx, regulates the NO−sGC−cGMP signaling pathway activity, and inhibits both pharmacological and electromechanical contraction of smooth muscle. Phenylaminojuglone AJ-2 is utilized in studies related to intestinal spasms.

CFM 1571 hydrochloride is a chemical compound that acts as a stimulator of the nitric oxide receptor known as soluble guanylate cyclase (sGC). It demonstrates an EC50 value of 5.49 μM and an IC50 value of 2.84 μM. Soluble guanylate cyclase is an important signal-transduction enzyme that is activated by nitric oxide. The compound CFM 1571 hydrochloride shows potential for use in cardiovascular and other disease research [1] [2].

Zagociguat (CY6463) is a soluble guanylate cyclase stimulator with central nervous system penetrance, enhancing nitric oxide (NO) signaling and used in the study of neurological diseases.

SGC agonist 1 is a potent soluble guanylate cyclase (SGC) agonist that enhances solubility and exhibits high cell permeability.

SGC agonist 2 is a potent soluble guanylate cyclase (SGC) agonist with potential therapeutic applications for cardiovascular diseases (heart failure, angina, pulmonary hypertension, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis).

BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator.